![Bernard Alliaume](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Bernard Alliaume is the founder of Epitopoietic Research Corp., which he founded in 2008 and where he holds the titles of CAO, Head-Human Resources & Vice President.
Currently, he is a Director at ERC-Belgium SA, where he has been working since 2008 and still holds the position.
Bernard Alliaume active positions
Companies | Position | Start |
---|---|---|
Epitopoietic Research Corp.
![]() Epitopoietic Research Corp. BiotechnologyHealth Technology Part of ERC-Belgium SA, Epitopoietic Research Corp. is a clinical stage emerging bio-pharmaceutical company based in Pasadena, CA. The company is developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with glioblastoma multiforme (GBM), the most deadliest form of brain cancer, using its patented Gliovac/ERC1671 vaccine. The company was founded by Bernard Alliaume, Apostolos Stathopoulos. Apostolos Stathopoulos has been the CEO since incorporation. | Founder | 2007-12-31 |
ERC-Belgium SA
![]() ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | Director/Board Member | 2008-12-28 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Epitopoietic Research Corp.
![]() Epitopoietic Research Corp. BiotechnologyHealth Technology Part of ERC-Belgium SA, Epitopoietic Research Corp. is a clinical stage emerging bio-pharmaceutical company based in Pasadena, CA. The company is developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with glioblastoma multiforme (GBM), the most deadliest form of brain cancer, using its patented Gliovac/ERC1671 vaccine. The company was founded by Bernard Alliaume, Apostolos Stathopoulos. Apostolos Stathopoulos has been the CEO since incorporation. | Health Technology |
ERC-Belgium SA
![]() ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | Health Technology |
- Stock Market
- Insiders
- Bernard Alliaume